Dagny Zhu1, Jesse L Berry2, Lilangi Ediriwickrema1, Kenneth Wong3, Thomas C Lee2, A Linn Murphree4, Jonathan W Kim2, Rima Jubran5. 1. University of Southern California Eye Institute, Calif., USA. 2. University of Southern California Eye Institute, Calif., USA; The Vision Center at Children's Hospital Los Angeles, Calif., USA. 3. Radiation Oncology Program, Children's Hospital, Los Angeles, Calif., USA. 4. The Vision Center at Children's Hospital Los Angeles, Calif., USA. 5. The Children's Center for Cancer and Blood Diseases, Children's Hospital, Calif., USA.
Abstract
BACKGROUND/AIMS: Chemoreduction protocols for retinoblastoma vary widely across institutions. Herein, we compare a 3- versus 6-cycle chemotherapy approach for group B retinoblastoma. METHODS: A nonrandomized, retrospective review of patients diagnosed with group B retinoblastoma from 1991-2011 at Children's Hospital Los Angeles was performed. A total of 72 eyes of 63 patients were analyzed. Mean follow-up time was 82 months (range 6-272 months). Main outcome measures were globe salvage and need for external beam radiation. RESULTS: Forty-six patients (55 eyes) were treated upfront with 3 cycles of carboplatin, etoposide, and vincristine; 17 patients (17 eyes) received 6 cycles. Thirty-seven eyes (67%) in the 3-cycle group were cured with initial chemoreduction alone. An additional 10 eyes with persistent or recurrent tumors were rescued with 3 more cycles for a total salvage rate of 85% (47/55 eyes). In the 6-cycle group, 16 of 17 eyes (94%) avoided radiation and enucleation. CONCLUSION: The initial recurrence rate was higher for the 3-cycle group (p = 0.03). However, eyes failing short-course chemoreduction were rescued with 3 additional cycles and achieved a similar overall event-free survival rate (p = 0.16). In our cohort, this short-course approach spared 63% (29/46) of patients with group B retinoblastoma the extra 3 cycles of systemic chemotherapy.
BACKGROUND/AIMS: Chemoreduction protocols for retinoblastoma vary widely across institutions. Herein, we compare a 3- versus 6-cycle chemotherapy approach for group B retinoblastoma. METHODS: A nonrandomized, retrospective review of patients diagnosed with group B retinoblastoma from 1991-2011 at Children's Hospital Los Angeles was performed. A total of 72 eyes of 63 patients were analyzed. Mean follow-up time was 82 months (range 6-272 months). Main outcome measures were globe salvage and need for external beam radiation. RESULTS: Forty-six patients (55 eyes) were treated upfront with 3 cycles of carboplatin, etoposide, and vincristine; 17 patients (17 eyes) received 6 cycles. Thirty-seven eyes (67%) in the 3-cycle group were cured with initial chemoreduction alone. An additional 10 eyes with persistent or recurrent tumors were rescued with 3 more cycles for a total salvage rate of 85% (47/55 eyes). In the 6-cycle group, 16 of 17 eyes (94%) avoided radiation and enucleation. CONCLUSION: The initial recurrence rate was higher for the 3-cycle group (p = 0.03). However, eyes failing short-course chemoreduction were rescued with 3 additional cycles and achieved a similar overall event-free survival rate (p = 0.16). In our cohort, this short-course approach spared 63% (29/46) of patients with group B retinoblastoma the extra 3 cycles of systemic chemotherapy.
Authors: Carlos Rodriguez-Galindo; Matthew W Wilson; Barrett G Haik; Thomas E Merchant; Catherine A Billups; Nirali Shah; Alvida Cain; James Langston; Mindy Lipson; Larry E Kun; Charles B Pratt Journal: J Clin Oncol Date: 2003-05-15 Impact factor: 44.544
Authors: Dan S Gombos; John Hungerford; David H Abramson; Judith Kingston; Guillermo Chantada; Ira J Dunkel; Celia B G Antoneli; Mark Greenwald; Barret G Haik; Carlos A Leal; Aurora Medina-Sanson; Amy C Schefler; Gavivann Veerakul; Regina Wieland; Norbert Bornfeld; Mathew W Wilson; Christopher Bing On Yu Journal: Ophthalmology Date: 2007-07 Impact factor: 12.079
Authors: Jesse L Berry; Kaitlin Kogachi; Hassan A Aziz; Kathleen McGovern; Emily Zolfaghari; A Linn Murphree; Rima Jubran; Jonathan W Kim Journal: Pediatr Blood Cancer Date: 2016-11-05 Impact factor: 3.167